How to commercialize a new strain
as a probiotic

Sign up for the webinar

August 28, 2025
10 AM EET (Eastern Europe)
9 AM CEST (Central Europe)

Speaker: 
Johanna Maukonen, D.Sc. (Tech)
Global Director of Clinical Innovation and Translation
IFF Health Sciences

Johanna will be talking about the path that is needed to commercialize a new strain as a probiotic. Starting from isolation of the strain from e.g.a clinical study, through strain characterization and safety assessments to move forward with manufacturing optimization, while also looking at the health efficacy potential from preclinical studies to human clinicals.

Note: This webinar was moved from June, 12 to the new date.
 

biosafe_webinar_12-6-2025_How-to-commercialize-a-new-strain-as-a-probiotic

Update your knowledge and sign up for the webinar

Sign up and secure your place. If the time is not right for you, we recommend signing up anyway. We will send a recording of the event to everyone who has registered.

Introduction

Biosafe's webinars are open and free for everyone interested in regulatory, safety or scientific issues surrounding regulated microbial products used in food and feed. Our webinars promote discussions, educate professionals and bring out interesting technologies or standards in the field. We welcome your ideas for future topics too.
Tune in and enjoy!

Please join the webinar early to make sure the connection works. 
If you have technical problems, please contact Teemu Kuhmonen.

Program and schedule

August 28, 2025
10 AM EET (Eastern Europe)
9 AM CEST (Central Europe)

Note: This webinar was moved from June, 12 to the new date.

How to commercialize a new strain as a probiotic

Speaker: 
Johanna Maukonen, D.Sc. (Tech)
Global Director of Clinical Innovation and Translation
IFF Health Sciences

Johanna leads Global Clinical Innovation and Translation, being a key link for Health R&D to customers and external scientific communities. Previously, she led Global Health and Nutrition Science group, which conducted and coordinated in vitro, pre-clinical and clinical studies on IFF’s ingredients. Before joining IFF, Johanna worked for over 20 years at VTT Technical Research Centre, Finland. She has extensive R&D experience in understanding the gut microbiota and its impact on health, especially on the influence of probiotics, nutrition and fibres.

Johanna will be talking about the path that is needed to commercialize a new strain as a probiotic. Starting from isolation of the strain from e.g.a clinical study, through strain characterization and safety assessments to move forward with manufacturing optimization, while also looking at the health efficacy potential from preclinical studies to human clinicals.

Sign up for the webinar

Share in social media:

Organized by:

Biosafe_logo_blue_web

 

More information:

Pauliina Halimaa, Managing Director, Biosafe

Biosafe Ltd is testing laboratory No. T356 accredited by FINAS Finnish Accreditation Service, accreditation requirement SFS-EN ISO/IEC 17025 (see accreditation certificate). Information on the activities within the scope of the accreditation is available at www.finas.fi